Ranolazine reduces atrial fibrillatory wave frequency

Eric W. Black-Maier, Sean D. Pokorney, Adam S. Barnett, Peter Liu, Peter Shrader, Jason Ng, Jeffrey Goldberger, Wojiech Zareba, James P. Daubert, Augustus O. Grant, Jonathan P. Piccini

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims Antiarrhythmic medications for the treatment of atrial fibrillation (AF) have limited efficacy and rare but potentially life-threatening side effects. Ranolazine is an antianginal agent that may have antiarrhythmic activity in AF. Methods and results Using the Duke Enterprise Data Unified Content Explorer database, we analysed a cohort of AF patients on ranolazine. Patients served as their own historic control. Electrocardiograms (ECGs) were analysed before and after ranolazine initiation to determine the effect of ranolazine on dominant frequency (DF), f-wave amplitude, and organizational index (OI). We identified 15 patients with ECGs in AF before and after ranolazine. Ranolazine was associated with lower DF by an average of 10% (5.10 ± 0.74 vs. 5.79 ± 0.96 Hz, P = 0.04) but not with changes in OI (0.47 ± 0.11 vs. 0.50 ± 0.12, P = 0.71) or amplitude (0.47 ± 0.43 vs. 0.41 ± 0.40 mV, P = 0.82). Ranolazine was also associated with lower DF in patients (n = 10) not on concomitant antiarrhythmic therapy (5.25 ± 0.78 vs. 6.03 ± 0.79 Hz, P = 0.04). Conclusion Ranolazine is associated with lower AF DF but no change in OI or fibrillatory wave amplitude. Prospective trials are needed to evaluate ranolazine's potential as a novel antiarrhythmic drug for AF.

Original languageEnglish (US)
Pages (from-to)1096-1100
Number of pages5
JournalEuropace
Volume19
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Atrial Fibrillation
Organizational Innovation
Electrocardiography
Ranolazine
Anti-Arrhythmia Agents
Databases
Therapeutics

Keywords

  • Antiarrhythmic
  • Atrial fibrillation
  • Dominant frequency
  • f-wave
  • Ranolazine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Black-Maier, E. W., Pokorney, S. D., Barnett, A. S., Liu, P., Shrader, P., Ng, J., ... Piccini, J. P. (2017). Ranolazine reduces atrial fibrillatory wave frequency. Europace, 19(7), 1096-1100. https://doi.org/10.1093/europace/euw200

Ranolazine reduces atrial fibrillatory wave frequency. / Black-Maier, Eric W.; Pokorney, Sean D.; Barnett, Adam S.; Liu, Peter; Shrader, Peter; Ng, Jason; Goldberger, Jeffrey; Zareba, Wojiech; Daubert, James P.; Grant, Augustus O.; Piccini, Jonathan P.

In: Europace, Vol. 19, No. 7, 01.07.2017, p. 1096-1100.

Research output: Contribution to journalArticle

Black-Maier, EW, Pokorney, SD, Barnett, AS, Liu, P, Shrader, P, Ng, J, Goldberger, J, Zareba, W, Daubert, JP, Grant, AO & Piccini, JP 2017, 'Ranolazine reduces atrial fibrillatory wave frequency', Europace, vol. 19, no. 7, pp. 1096-1100. https://doi.org/10.1093/europace/euw200
Black-Maier EW, Pokorney SD, Barnett AS, Liu P, Shrader P, Ng J et al. Ranolazine reduces atrial fibrillatory wave frequency. Europace. 2017 Jul 1;19(7):1096-1100. https://doi.org/10.1093/europace/euw200
Black-Maier, Eric W. ; Pokorney, Sean D. ; Barnett, Adam S. ; Liu, Peter ; Shrader, Peter ; Ng, Jason ; Goldberger, Jeffrey ; Zareba, Wojiech ; Daubert, James P. ; Grant, Augustus O. ; Piccini, Jonathan P. / Ranolazine reduces atrial fibrillatory wave frequency. In: Europace. 2017 ; Vol. 19, No. 7. pp. 1096-1100.
@article{fa6608d77be74e7b893f48e874d8c366,
title = "Ranolazine reduces atrial fibrillatory wave frequency",
abstract = "Aims Antiarrhythmic medications for the treatment of atrial fibrillation (AF) have limited efficacy and rare but potentially life-threatening side effects. Ranolazine is an antianginal agent that may have antiarrhythmic activity in AF. Methods and results Using the Duke Enterprise Data Unified Content Explorer database, we analysed a cohort of AF patients on ranolazine. Patients served as their own historic control. Electrocardiograms (ECGs) were analysed before and after ranolazine initiation to determine the effect of ranolazine on dominant frequency (DF), f-wave amplitude, and organizational index (OI). We identified 15 patients with ECGs in AF before and after ranolazine. Ranolazine was associated with lower DF by an average of 10{\%} (5.10 ± 0.74 vs. 5.79 ± 0.96 Hz, P = 0.04) but not with changes in OI (0.47 ± 0.11 vs. 0.50 ± 0.12, P = 0.71) or amplitude (0.47 ± 0.43 vs. 0.41 ± 0.40 mV, P = 0.82). Ranolazine was also associated with lower DF in patients (n = 10) not on concomitant antiarrhythmic therapy (5.25 ± 0.78 vs. 6.03 ± 0.79 Hz, P = 0.04). Conclusion Ranolazine is associated with lower AF DF but no change in OI or fibrillatory wave amplitude. Prospective trials are needed to evaluate ranolazine's potential as a novel antiarrhythmic drug for AF.",
keywords = "Antiarrhythmic, Atrial fibrillation, Dominant frequency, f-wave, Ranolazine",
author = "Black-Maier, {Eric W.} and Pokorney, {Sean D.} and Barnett, {Adam S.} and Peter Liu and Peter Shrader and Jason Ng and Jeffrey Goldberger and Wojiech Zareba and Daubert, {James P.} and Grant, {Augustus O.} and Piccini, {Jonathan P.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1093/europace/euw200",
language = "English (US)",
volume = "19",
pages = "1096--1100",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Ranolazine reduces atrial fibrillatory wave frequency

AU - Black-Maier, Eric W.

AU - Pokorney, Sean D.

AU - Barnett, Adam S.

AU - Liu, Peter

AU - Shrader, Peter

AU - Ng, Jason

AU - Goldberger, Jeffrey

AU - Zareba, Wojiech

AU - Daubert, James P.

AU - Grant, Augustus O.

AU - Piccini, Jonathan P.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Aims Antiarrhythmic medications for the treatment of atrial fibrillation (AF) have limited efficacy and rare but potentially life-threatening side effects. Ranolazine is an antianginal agent that may have antiarrhythmic activity in AF. Methods and results Using the Duke Enterprise Data Unified Content Explorer database, we analysed a cohort of AF patients on ranolazine. Patients served as their own historic control. Electrocardiograms (ECGs) were analysed before and after ranolazine initiation to determine the effect of ranolazine on dominant frequency (DF), f-wave amplitude, and organizational index (OI). We identified 15 patients with ECGs in AF before and after ranolazine. Ranolazine was associated with lower DF by an average of 10% (5.10 ± 0.74 vs. 5.79 ± 0.96 Hz, P = 0.04) but not with changes in OI (0.47 ± 0.11 vs. 0.50 ± 0.12, P = 0.71) or amplitude (0.47 ± 0.43 vs. 0.41 ± 0.40 mV, P = 0.82). Ranolazine was also associated with lower DF in patients (n = 10) not on concomitant antiarrhythmic therapy (5.25 ± 0.78 vs. 6.03 ± 0.79 Hz, P = 0.04). Conclusion Ranolazine is associated with lower AF DF but no change in OI or fibrillatory wave amplitude. Prospective trials are needed to evaluate ranolazine's potential as a novel antiarrhythmic drug for AF.

AB - Aims Antiarrhythmic medications for the treatment of atrial fibrillation (AF) have limited efficacy and rare but potentially life-threatening side effects. Ranolazine is an antianginal agent that may have antiarrhythmic activity in AF. Methods and results Using the Duke Enterprise Data Unified Content Explorer database, we analysed a cohort of AF patients on ranolazine. Patients served as their own historic control. Electrocardiograms (ECGs) were analysed before and after ranolazine initiation to determine the effect of ranolazine on dominant frequency (DF), f-wave amplitude, and organizational index (OI). We identified 15 patients with ECGs in AF before and after ranolazine. Ranolazine was associated with lower DF by an average of 10% (5.10 ± 0.74 vs. 5.79 ± 0.96 Hz, P = 0.04) but not with changes in OI (0.47 ± 0.11 vs. 0.50 ± 0.12, P = 0.71) or amplitude (0.47 ± 0.43 vs. 0.41 ± 0.40 mV, P = 0.82). Ranolazine was also associated with lower DF in patients (n = 10) not on concomitant antiarrhythmic therapy (5.25 ± 0.78 vs. 6.03 ± 0.79 Hz, P = 0.04). Conclusion Ranolazine is associated with lower AF DF but no change in OI or fibrillatory wave amplitude. Prospective trials are needed to evaluate ranolazine's potential as a novel antiarrhythmic drug for AF.

KW - Antiarrhythmic

KW - Atrial fibrillation

KW - Dominant frequency

KW - f-wave

KW - Ranolazine

UR - http://www.scopus.com/inward/record.url?scp=85026413949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026413949&partnerID=8YFLogxK

U2 - 10.1093/europace/euw200

DO - 10.1093/europace/euw200

M3 - Article

VL - 19

SP - 1096

EP - 1100

JO - Europace

JF - Europace

SN - 1099-5129

IS - 7

ER -